Drugs / TOP-N53
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06954597 | Feb 2025 → Oct 2026 expected | systemic sclerosis | Topadur Pharma AG | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOP-N53 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06954597 ↗ |
| Action | Inhibit | “TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor” NCT06954597 ↗ |
| Route | Topical | “applied topically directly” NCT06954597 ↗ |